COVID-19 with essential thrombocythemia treated with apixaban for antithrombotic prophylaxis

A 40-year-old man was admitted to our hospital for COVID-19. He had been treated for essential thrombocythemia (ET). He was diagnosed severe illness of COVID-19, oxygen therapy and dexamethasone were administered. There was a possibility of thromboembolic events in this case, apixaban for prophylaxi...

Full description

Saved in:
Bibliographic Details
Published inBMJ case reports Vol. 14; no. 11; p. e246700
Main Authors Takasaki, Kazuki, Tsunenari, Takazumi, Mori, Kazuma, Aochi, Satsuki
Format Journal Article
LanguageEnglish
Published London BMJ Publishing Group LTD 30.11.2021
BMJ Publishing Group
Subjects
Blood
Blood platelets
Case Report
Case reports
Coronaviruses
COVID-19
Disease prevention
Drug dosages
Hospitals
Mortality
Patients
Severe acute respiratory syndrome coronavirus 2
Thromboembolism
Thrombosis
Tumors
Japan
Online AccessGet full text

Cover

More Information
Summary:A 40-year-old man was admitted to our hospital for COVID-19. He had been treated for essential thrombocythemia (ET). He was diagnosed severe illness of COVID-19, oxygen therapy and dexamethasone were administered. There was a possibility of thromboembolic events in this case, apixaban for prophylaxis was added. With these treatments, the patient has made a good recovery, and he was discharged on hospital day 11. There is no standard strategy for prophylaxis of thrombosis in patients with ET, and apixaban could be a clinical benefit for these patients.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:1757-790X
1757-790X
DOI:10.1136/bcr-2021-246700